Danaher (NYSE:DHR) Announces Earnings Results

Danaher (NYSE:DHR) issued its quarterly earnings results on Tuesday. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20, Briefing.com reports. Danaher had a net margin of 16.78% and a return on equity of 11.48%. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same period in the prior year, the firm earned $2.36 earnings per share. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year.

Danaher Price Performance

DHR stock opened at $250.41 on Thursday. The company has a market capitalization of $185.44 billion, a P/E ratio of 42.44, a PEG ratio of 4.24 and a beta of 0.83. Danaher has a twelve month low of $182.09 and a twelve month high of $259.00. The business has a 50 day simple moving average of $249.00 and a 200-day simple moving average of $230.78. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a $0.27 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher’s dividend payout ratio is presently 18.31%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent research reports. Raymond James upped their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. TD Cowen upped their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday. Robert W. Baird upped their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Bank of America upped their target price on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday. Six research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $270.00.

Insider Activity

In other news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,957 shares of company stock valued at $8,265,802. 11.10% of the stock is currently owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.